Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, myeloid neoplasm, neoplasm	Recruiting	Phase 1 / Phase 2	2026-04-29		NCT04501120

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ascentage Pharma Group Inc.	30
Suzhou Yasheng Pharmaceutical Co., Ltd.	8

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chongqing University Cancer Hospital	Chongqing	China	33
Guangdong Provincial People's Hospital	Guangzhou	China	85
Henan Tumor Hospital	Zhengzhou	China	2
Peking University People's Hospital	Beijing	China	146
Shanghai The Sixth People' s Hospital	Shanghai	China	1
Sun Yat-sen University Cancer Center	Guangzhou	China	1
The First Affiliated Hospital of Soochow University	Suzhou	China	42
The First Affiliated Hospital, College of Medicine, Zhejiang University	Hangzhou	China	12
Union Hospital medical college Huazhong University of Science and Technology	Wuhan	China	2
West China Hospital of Sichuan University	Chengdu	China	17
Xiangya Hospital Central South University	Changsha	China	27
Zhongnan Hospital of Hunan university	Wuhan	China	1